In its second-quarter earnings release, Nuvation Bio Inc. (NYSE:NUVB) announced that it has decided to halt work on NUV-868, its BD2-selective BET inhibitor, while considering the program’s future. The company said it concluded the Phase 1b dose escalation study of NUV-868 in combination with AstraZeneca Plc (NASDAQ:AZN)-Merck & Co Inc’s (NYSE:MRK) Lynparza (olaparib) for ovarian, pancreatic, metastatic castration-resistant prostate (mCRPC), triple-negative breast cancer, and other solid tumors, and with Pfizer Inc (NYSE:PFE)-Astellas Pharma Inc’s (OTC:ALPMF) (OTC:ALPMY) Xtandi (enzalutamide) for mCRPC. The company completed an internal analysis of efficacy and safety data from Phase 1 monotherapy and Phase 1b combination studies of NUV-868. Following this analysis, Nuvation Bio decided not to initiate a Phase 2 study of NUV-868 as a monotherapy or combined with ...